HC Wainwright Weighs in on Homology Medicines, Inc.’s FY2026 Earnings (NASDAQ:FIXX)

Homology Medicines, Inc. (NASDAQ:FIXX – Get Rating) – Research analysts at HC Wainwright cut their FY2026 earnings estimates for shares of Homology Medicines in a note issued to investors on Thursday, March 16th. HC Wainwright analyst P. Trucchio now anticipates that the company will earn $0.17 per share for the year, down from their prior estimate of $0.28. HC Wainwright currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for Homology Medicines’ current full-year earnings is ($2.00) per share.

Homology Medicines Trading Down 3.1 %

Shares of NASDAQ:FIXX opened at $0.95 on Friday. The company has a 50 day moving average of $1.47 and a 200-day moving average of $1.54. The firm has a market cap of $54.80 million, a P/E ratio of -8.64 and a beta of -0.01. Homology Medicines has a twelve month low of $0.95 and a twelve month high of $3.57.

Institutional Trading of Homology Medicines

Institutional investors have recently made changes to their positions in the stock. Virtu Financial LLC acquired a new stake in Homology Medicines during the second quarter valued at approximately $34,000. Marshall Wace LLP lifted its stake in Homology Medicines by 40.4% during the third quarter. Marshall Wace LLP now owns 30,175 shares of the company’s stock valued at $48,000 after purchasing an additional 8,689 shares during the last quarter. Raymond James & Associates acquired a new stake in Homology Medicines during the first quarter valued at approximately $51,000. Mirabella Financial Services LLP acquired a new stake in Homology Medicines during the first quarter valued at approximately $53,000. Finally, Cubist Systematic Strategies LLC acquired a new stake in Homology Medicines during the second quarter valued at approximately $55,000. 40.73% of the stock is owned by institutional investors and hedge funds.

Homology Medicines Company Profile

(Get Rating)

Homology Medicines, Inc is a clinical-stage genetic medicines company, which engages in the translation of proprietary gene editing and gene therapy technology into novel treatments for patients with rare genetic diseases. The company was founded in March 2015 and is headquartered in Bedford, MA.